PMID- 23700793
OWN - NLM
STAT- MEDLINE
DCOM- 20130626
LR  - 20181202
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 68
IP  - 4
DP  - 2013 Apr
TI  - Pioglitazone ameliorates palmitate induced impairment of mitochondrial morphology 
      and function and restores insulin level in beta cells.
PG  - 270-3
AB  - This study aimed to investigate the effect of pioglitazone (PIO) on insulin 
      secretion and mitochondrial ultrastructure and function in 3 cells. HIT-T15 cells 
      were treated with control or palmitate (free fat acids, FFA) or/and PIO and 
      divided into 7 groups: Control group; 0.5 mmol/l FFA (LF); 0.5 mmol/l FFA plus 
      10-7 mol/I PIO (LFLP); 0.5 mmol/l FFA plus 10-5mol/I PIO (LFHP); 1.0 mmol/l FFA 
      (HF); 1.0 mmol/l FFA plus 10-7mol/I PIO (HFLP); 1.0 mmol/l FFA plus 10-5 mol/I 
      PIO (HFHP). Apoptotic peaks, mitochondrial ultrastructure, ATP/ADP, mRNA levels 
      of peroxisome proliferater activated receptor gamma coactivator-1 (PGC-1) and 
      nucleus respiratory factor-1 (NRF-1) as well as insulin secretion were measured. 
      The results showed that palmitate impaired mitochondrion structure, which could 
      be alleviated by PIO. Palmitate could increase apoptotic peaks, decrease ATP/ADP 
      ratio, enhance the expression of PGC-1 mRNA and NRF-1 mRNA, and decrease glucose 
      stimulated insulin secretion (GSIS). In contrast, PIO could decrease apoptotic 
      peaks, restore partly ATP/ADP ratio, decrease the expression of PGC-1 mRNA and 
      NRF-1 mRNA, and increase GSIS level. These results demonstrate that PIO could 
      ameliorate palmitate induced damage to mitochondrion ultrastructure and function 
      and restore GSIS, accompanied by the modulation of PGC-1 and NRF-1 expression. 
      These findings provide new insight into the hypoglycemic effects of PIO and help 
      develop new agents for diabetes therapy.
FAU - Li, Yao
AU  - Li Y
AD  - The First Affiliated Hospital of Chengdu Medical College, Huaxi Hospital of 
      Sichuan University, Chengdu, China.
FAU - Zhang, Xinxia
AU  - Zhang X
FAU - Tong, Nanwei
AU  - Tong N
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Heat-Shock Proteins)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Indicators and Reagents)
RN  - 0 (Insulin)
RN  - 0 (NRF1 protein, human)
RN  - 0 (Nuclear Respiratory Factor 1)
RN  - 0 (PPARGC1A protein, human)
RN  - 0 (Palmitates)
RN  - 0 (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha)
RN  - 0 (Thiazolidinediones)
RN  - 0 (Transcription Factors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Adenosine Diphosphate/metabolism
MH  - Adenosine Triphosphate/metabolism
MH  - Apoptosis/drug effects
MH  - Cell Line
MH  - Chromatography, High Pressure Liquid
MH  - Flow Cytometry
MH  - Heat-Shock Proteins/biosynthesis
MH  - Humans
MH  - Hypoglycemic Agents/*pharmacology
MH  - In Situ Nick-End Labeling
MH  - Indicators and Reagents
MH  - Insulin/*metabolism
MH  - Insulin-Secreting Cells/drug effects/*metabolism/ultrastructure
MH  - Microscopy, Electron
MH  - Mitochondria/drug effects/*ultrastructure
MH  - Nuclear Respiratory Factor 1/biosynthesis
MH  - Palmitates/*antagonists & inhibitors/*toxicity
MH  - Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
MH  - Pioglitazone
MH  - Real-Time Polymerase Chain Reaction
MH  - Thiazolidinediones/*pharmacology
MH  - Transcription Factors/biosynthesis
EDAT- 2013/05/25 06:00
MHDA- 2013/06/28 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/05/25 06:00 [entrez]
PHST- 2013/05/25 06:00 [pubmed]
PHST- 2013/06/28 06:00 [medline]
PST - ppublish
SO  - Pharmazie. 2013 Apr;68(4):270-3.